Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
valsartan + rosuvastatin
- Development stage
- Discontinued
- Lead developer
- LG Chem
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Valsartan + rosuvastatin is a fixed-dose combination of two small molecule drugs used for the concomitant treatment of hypertension and hyperlipidemia. Valsartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by selectively inhibiting the angiotensin II type 1 (AT1) receptor, thereby blocking vasoconstriction and aldosterone-secreting effects of angiotensin II. Rosuvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to reduced plasma LDL cholesterol levels. The combination provides additive benefits in lowering both blood pressure and LDL cholesterol compared to either drug alone, with studies showing efficacy and safety in patients with coexisting hypertension and dyslipidemia[1][2][3].
- Brand names
- Rovatitan
- Other names
- valsartan/rosuvastatinrosuvastatin/valsartan
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on valsartan + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on valsartan + rosuvastatin.